Cargando…
Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up
INTRODUCTION: Autoimmune pulmonary alveolar proteinosis (aPAP) is a disease caused by IgG antibodies against granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Whole lung lavage (WLL) allows to remove the lipo‐proteinaceous material accumulated by the poor clearance of alveolar surfactant. H...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542988/ https://www.ncbi.nlm.nih.gov/pubmed/37300395 http://dx.doi.org/10.1111/crj.13650 |
_version_ | 1785114202725154816 |
---|---|
author | Oterino‐Moreira, Iván Linares‐Asensio, María‐Jesús Sanz‐Márquez, Sira Pérez‐Encinas, Montserrat |
author_facet | Oterino‐Moreira, Iván Linares‐Asensio, María‐Jesús Sanz‐Márquez, Sira Pérez‐Encinas, Montserrat |
author_sort | Oterino‐Moreira, Iván |
collection | PubMed |
description | INTRODUCTION: Autoimmune pulmonary alveolar proteinosis (aPAP) is a disease caused by IgG antibodies against granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Whole lung lavage (WLL) allows to remove the lipo‐proteinaceous material accumulated by the poor clearance of alveolar surfactant. However, it is a complex technique that is not exempt from complications, and in some cases, the patients are refractory, requiring the performance of several WLLs spaced apart in time. MATERIALS AND METHODS: We present the clinical, functional, and radiological evolution after 24 months of follow‐up of a patient diagnosis of aPAP refractory to WLL, with performed three therapeutic WLLs spaced 16 and 36 months and serious potentially fatal complications in the last one. RESULTS AND DISSCUSION: After 24 months, no adverse effects have appeared and the great clinical, functional and radiological response is maintained. The patient has been successfully treated with inhaled recombinant human GM‐CSF sargramostim. |
format | Online Article Text |
id | pubmed-10542988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105429882023-10-03 Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up Oterino‐Moreira, Iván Linares‐Asensio, María‐Jesús Sanz‐Márquez, Sira Pérez‐Encinas, Montserrat Clin Respir J Brief Reports INTRODUCTION: Autoimmune pulmonary alveolar proteinosis (aPAP) is a disease caused by IgG antibodies against granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Whole lung lavage (WLL) allows to remove the lipo‐proteinaceous material accumulated by the poor clearance of alveolar surfactant. However, it is a complex technique that is not exempt from complications, and in some cases, the patients are refractory, requiring the performance of several WLLs spaced apart in time. MATERIALS AND METHODS: We present the clinical, functional, and radiological evolution after 24 months of follow‐up of a patient diagnosis of aPAP refractory to WLL, with performed three therapeutic WLLs spaced 16 and 36 months and serious potentially fatal complications in the last one. RESULTS AND DISSCUSION: After 24 months, no adverse effects have appeared and the great clinical, functional and radiological response is maintained. The patient has been successfully treated with inhaled recombinant human GM‐CSF sargramostim. John Wiley and Sons Inc. 2023-06-10 /pmc/articles/PMC10542988/ /pubmed/37300395 http://dx.doi.org/10.1111/crj.13650 Text en © 2023 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Reports Oterino‐Moreira, Iván Linares‐Asensio, María‐Jesús Sanz‐Márquez, Sira Pérez‐Encinas, Montserrat Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
title | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
title_full | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
title_fullStr | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
title_full_unstemmed | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
title_short | Response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
title_sort | response to inhaled granulocyte‐macrophage colony‐stimulating factor in patient with mild‐to‐moderate autoimmune pulmonary alveolar proteinosis—24 months of follow‐up |
topic | Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542988/ https://www.ncbi.nlm.nih.gov/pubmed/37300395 http://dx.doi.org/10.1111/crj.13650 |
work_keys_str_mv | AT oterinomoreiraivan responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup AT linaresasensiomariajesus responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup AT sanzmarquezsira responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup AT perezencinasmontserrat responsetoinhaledgranulocytemacrophagecolonystimulatingfactorinpatientwithmildtomoderateautoimmunepulmonaryalveolarproteinosis24monthsoffollowup |